

**DRUG PRIOR AUTHORIZATION COMMITTEE MEETING**  
**September 20, 2018**  
**Missouri Coalition for Community Behavioral Healthcare,**  
**Lower Level CEO Room,**  
**Jefferson City, MO**

**Committee Members Present**

Conrad Balcer, D.O., Chair  
Laura Kingsley, Pharm D  
Laine Young-Walker, MD  
Pat Bryant, Pharm D

**Guest of Committee Member**

Dennis Mowry, Drug Information Fellow  
at UMKC Drug Information Center  
attended with Patrick Bryant.

**MO HealthNet Staff Present:**

Jennifer Tidball, Acting Director  
Mark Roaseau, R.Ph, Clinical Pharmacist  
Sharie Hahn, Special Counsel  
Jessica Veit, RN, Clinical Management  
Angela Wilson, Pharmacy Operations  
Manager  
Frances (Franki) Moseley, Administrative  
Office Support Assistant  
Beth Mitchell, Administrative Office  
Support Assistant  
Mitch Ruth, Pharmacy Fiscal Unit  
Manager

Dr. Timothy Kling, MD, Assistant Medical  
Director  
Lisa E. Smith, Program Development  
Specialist  
Jackie Hickman, Drug Rebate Unit  
Supervisor  
Kari Ballew, Drug Rebate Unit Medicaid  
Specialist  
Elizabeth Short, Program Specialist

**Contractors in Attendance:**

Joshua Moore, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Janelle Sheen, Pharm D, Conduent  
Sandy Kapur, Pharm D, Conduent  
Olivia Rush, Pharm D, Conduent  
Geri Roling, Wipro  
Chelsea Pendleton, Wipro

**Others Attending:**

Ashley Polce, Abbvie  
Michael Lafond, Abbvie  
Evan Rushing, Alkermes

Kristi Kemp, Allergan  
CamilleKerr, Amgen  
Christina Brandmeyer, Amgen  
Janene Verrant, Astra Zeneca  
Kin Wine, Avexi  
Randy McGinley, Bayer  
Aaron Shaw, Boehringer Ingelehim  
Chi Kohuhoff, Braeburn  
M. Laurie, Bristol Meyer Squibb  
Lisa Tootle, Bristol-Myer Squibb  
Tom Gayer, Eli Lilly  
Garth Wright, Genentech  
Jennifer Stoffe, Janssen  
Mark Herlent, Lundbeck  
Mark Forkner, Lundbeck  
Berend Koops, Merck  
Stephanie Witle, MO Ins Coalition  
Kim Mure, MPA  
Gena Terlizzi, NAMI  
Evie Kniseley, Novartis  
Matt Bradley, Novartis  
Heather Maniska, UHC  
Mary Jo Deflaro

<b>Welcome, Introductions and Opening Remarks</b>	Conrad Balcer, Chair, called the meeting to order. Mark Roaseau introduced himself and started the introductions and opening remarks. Mark introduced two new employees, Beth Mitchell, Administrative Assistant, Jessica Viet, RN, Case Manager. Guest Dennis Mowry, Drug Information Fellow at UMKC Drug Information Center attended with Patrick Bryant.
<b>Minutes Approval</b>	Minutes of the June 2018 Drug PA meeting were reviewed and approved. Laine Young-Walker made the motion and Pat Bryant seconded the motion. (See Roll Call Vote)
<b>Pharmacy Program/Budget Update</b>	Mitch Ruth presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.
<b>Old Business</b>	
<b>Old Business Implementation Schedule</b>	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included March/April, 2018 PDL decisions to be implemented July 2018. Pending ratification, PDL decisions from the June 2018 Drug PA Committee meeting will be implemented October 2018. New PDL will be implemented January 2019 with exception, Oral Oncology 15 day implementation on November 6, 2018. Schedules may be found on the MHD web page at <a href="https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf">https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf</a>
<b>New Business</b>	
<b>New Drug Review</b>	<p>Mark Roaseau reviewed the new products identified for the quarter April, May and June, 2018 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> <li>• <b>Discussion</b> – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending.</li> <li>• <b>Public Hearing</b> –</li> <li>• <b>Decision</b> – Members voted to accept the new product recommendations as presented. (See Roll Call Vote)</li> </ul>

<b>Clinical Edits</b>	
<b>Aimovig Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document.</li> <li>• <b>Public Hearing</b> –.</li> <li>• <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>
<b>Crysvita Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document.</li> <li>• <b>Public Hearing</b> – Lonnie Givens represented Ultragenics</li> <li>• <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>
<b>Jynarque Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document.</li> <li>• <b>Public Hearing</b> – Rick Kegler represented Otsuka</li> <li>• <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>
<b>Palynziq Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. Conrad would like a percentage of people whom would need this drug. (See Roll Call Vote)</li> </ul>
<b>Oral Oncology 15 Day Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. suggestion made for package restrictions.</li> <li>• <b>Public Hearing</b> – No Comments Entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented adding package restrictions. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List (PDL)</b>	
<b>ACE Inhibitors/Calcium Channel Blocker Combination Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No Comments Entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>ACE Inhibitors and ACE Inhibitors Diuretic Combination Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>ADHD Therapy Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – Justin Barnes represented Trsipharma discussed Dynavael XR.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>ARB and ARB Diuretic Combination Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Angiotensin II Receptor/Calcium Channel blocker Combination Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Anticoagulant Agents: Oral and Subcutaneous</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Antiplatelet Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b><u>Beta Adrenergic</u> Blocker and <u>Beta Adrenergic</u> Blocker Diuretic Combination Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – Daisy Dai represented Pierre Fabre spoke about Hemangeol, Chris Rofidal, Pierre Fabre</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL With the following changes, Hemangeol preferred for the indication of proliferating infantile hemangioma requiring systemic therapy with treatment initiated at ages 5 weeks to 5 months. (See Roll Call Vote)</li> </ul>
<b>Calcium Channel Blockers Dihydropyridines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote))</li> </ul>
<b>Calcium Channel Blocker Agents (Non-Dihydropyridines)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Direct Renin Inhibitors and Direct Renin Inhibitors Combination Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No Comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Lipotropic Agents: Homozygous Familial Hypercholesterolemia Products</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Lipotropic Agnets: Niacin Derivatives</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Lipotropic Agents: Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Lipotropic Agents: Triglyceride Lowering Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Proton Pump Inhibitor Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Pulmonary Arterial Hypertension (PHA) Agents: Oral</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – Zev Winicar spoke on Orenitram from United Therapeutics</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Sympatholytic Antihypertensive Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List Announcement</b>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: <a href="http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf">http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</a></p>

<b>Conduent Update</b>	<p>Conduent did present the following items for review. These items were included in the packet for the meeting. Here is the list:</p> <ul style="list-style-type: none"> <li>• Call Center Statistics, Claims, Spend, and Diagnosis information for the SSRI's and SNRI's.</li> <li>• New Drug Summary.</li> </ul>
<b>Program Utilization: Top 25 Drugs Summary</b>	<p>The Top 25 Drugs Summary Reports for the 1st, 2<sup>nd</sup>, 3<sup>rd</sup>, &amp; 4th quarter 2017 were provided in the packets for review. Two versions were provided: one report ranked drug spend by dollars and the other by utilization/claims.</p>
<b>Call Center Statistics/ Cyber Access Reports</b>	<p>In the packets provided for the meeting were the following handouts and reports:</p> <ul style="list-style-type: none"> <li>• A handout detailing pharmacy help desk call center activity</li> <li>• Cyber Access Active User Counts and Logging Information.</li> <li>• Reports were also provided detailing the number and type of prescribers and active users on Cyber Access.</li> </ul>
<b>Adjourn</b>	<p>The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call) The next meeting of the <b>Drug Prior Authorization Committee</b> is scheduled for <b>December 20, 2018 at the Missouri Coalition for Community Behavioral Healthcare Building, Lower Level CEO Room, 221 Metro Drive, Jefferson City, MO.</b></p>

<b><u>Roll Call for September 20, 2018</u></b>							
<b><u>Member</u></b>	<b>Minutes</b>	<b>Aimovig</b>	<b>Crysvita</b>	<b>Jynarque</b>	<b>Palynziq</b>	<b>Oral Oncology</b>	<b>ACE Inhibitors/ Calcium Channel</b>
<b>Conrad Balcer, D.O.</b>	Y	Y	Y	Y	Y	Y	Y
<b>Pat Bryant, Pharm D</b>	S Y	M Y	S Y	S Y	M Y	S Y	M Y
<b>Laine Young- Walker, M.D.</b>	M Y	S Y	M Y	M Y	S Y	S Y	Y
<b>Morgan Sperry, Pharm D-Alternate</b>							
<b>Jennifer Kemp- Ostreich, Pharm D</b>	A	A	A	A	A	A	A
<b>Laura Kingsley, Pharm D</b>	Not present	Not present	Not present	Y	Y	M Y	S Y

<u>Member</u>	ACE Inhibitors /Diuretic	ADHD Therapy	Angiotensin Receptor Blocker/ Diuretic	Angiotensin Receptor/Calcium	Anticoagulant Agents Oral & Subcutaneous	Antiplatelet Agents	Beta Adrenergic Blockers and Diuretic
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	Y	Y	MY	SY	Y	MY	SY
Laine Young-Walker, M.D.	MY	SY	Y	MY	MY	Y	MY
Morgan Sperry, Pharm D-Alternate							
Jennifer Kemp-Ostreich, Pharm D	A	A	A	A	A	A	A
Laura Kingsley, Pharm D	SY	MY	SY	Y	SY	SY	
<u>Member</u>	Calcium Channel Blocker	Calcium Channel Blocker/Non dihydrophyridines	Direct Renin Inhibitors	Lipotropic Agents: Homozygous Familial	Lipotrapic Agents: Niacin Derivatives	Lopotrapic PCSK9	Lipotropic Agents: Statins
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	Y	Y	SY	MY	Y	Y	MY
Laine Young-Walker, M.D.	MY	MY	Y	SY	MY	MY	SY
Morgan Sperry, Pharm D-Alternate							
Jennifer Kemp-Ostreich, Pharm D	A	A	A	A	A	A	A
Laura Kingsley, Pharm D	SY	SY	MY	Y	SY	SY	Y

<u>Member</u>	Lipotropic Agents: Triglyceride Lowering	Proton Pump Inhibitor Agents	Pulmonary Arterial Hypertension Inhaled	Pulmonary Arterial Hypertension Oral	Sympatholytic Antihypertensive Agents	meeting adjourn	Executive Session
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	SY	SY	Y	Y	SY	SY	MY
Laine Young-Walker, M.D.	Y	MY	MY	MY	Y	MY	SY
Morgan Sperry, Pharm D-Alternate							
Jennifer Kemp-Ostreich, Pharm D	A	A	A	A	A	A	A
Laura Kingsley, Pharm D	MY	Y	SY	SY	MY	Y	Y

**Roll Call Abbreviations:**

**A-Absent**

**AL-Alternate**

**R-Ratify**

**M-Motion**

**S-Second**

**Y-Yes to the vote**